cmAngio® vs VX1+
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary objective is to integrate cardiovascular risk assessment into routine breast imaging workflows. This AI software efficiently detects Breast Arterial Calcifications (BAC) on standard mammograms (FFDM and DBT), providing valuable insights into a woman's cardiovascular health without requiring additional radiation or procedures. It is ideal for identifying patients who may benefit from further cardiovascular evaluation based on existing imaging data.
View cmAngio® →Choose VX1+ if…
Choose VX1+ if you are an electrophysiologist performing cardiac ablation procedures for atrial fibrillation or atrial tachycardia and require real-time AI-powered assistance. This software helps identify abnormal electrograms (dispersed electrograms) on 3D anatomical and electrical maps during the procedure, enhancing precision and guiding ablation strategy. It is best suited for improving the efficiency and effectiveness of complex EP interventions by providing immediate, actionable insights.
View VX1+ →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | VX1+ |
|---|---|---|
| Pricing | Paid, out-of-pocket | Unknown |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Software, compatible with most multipolar catheters and mapping technologies used in operating rooms or electrophysiology labs. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool A emphasizes rapid, non-disruptive integration with existing imaging workflows, boasting installation in less than an hour and compatibility with any DICOM-compliant viewer. While Tool B highlights a simple user interface and integration with specific EP systems, Tool A's broader compatibility and quick setup suggest a more universally user-friendly initial experience for a wider range of clinical settings.
Clinical Value
VX1+Tool B provides real-time AI assistance during complex, interventional cardiac ablation procedures for atrial fibrillation and tachycardia, directly impacting immediate procedural outcomes. Tool A offers valuable, non-invasive cardiovascular risk assessment from existing mammograms, which is crucial for preventative care but less immediate in its clinical application than Tool B's real-time guidance during an active intervention.
Pricing & Value
cmAngio®Both tools lack publicly available pricing details. However, Tool A explicitly mentions the availability of 'limited-time offers for no-cost implementation and service,' which suggests a potentially more accessible or flexible initial pricing model. This offers a slight advantage in terms of transparency and potential initial value compared to Tool B, which provides no such indications.
Enterprise Readiness
cmAngio®Tool A explicitly states it is HIPAA-compliant and cybersecure, and mentions contacting the vendor for Business Associate Agreement (BAA) details, which are critical for enterprise deployment. While Tool B is FDA-cleared, its HIPAA compliance and BAA are only 'expected' and not explicitly stated in the provided facts, making Tool A appear more explicitly prepared for enterprise integration.
Innovation
VX1+Tool B's application of AI to provide real-time, actionable guidance during a complex, interventional cardiac ablation procedure represents a high degree of innovation in a high-stakes clinical setting. While Tool A innovatively extracts new cardiovascular risk insights from existing mammograms, Tool B's real-time procedural guidance offers a more immediate and technically complex advancement in patient care.
Support & Docs
TieNeither the provided structured facts nor web searches offer specific details or comparative advantages regarding the support and documentation for either tool. Both companies generally state they offer support and training, but without further specific information, it is not possible to distinguish between them.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | VX1+ |
|---|---|---|
| Name | cmAngiou00ae | VX1+ |
| Company | CureMetrix | Volta Medical |
| Primary Purpose | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | AI-powered software that assists electrophysiologists in real-time identification of abnormal electrograms during cardiac ablation procedures for atrial fibrillation and atrial tachycardia. |
| Key Detection/Assistance | AI-based detection of Breast Arterial Calcifications (BAC), processes FFDM and DBT exams, provides visualization of BAC location on a scorecard. | Real-time manual or automatic annotation of 3D anatomical and electrical maps of the human heart, identification of spatio-temporal dispersed electrograms (DEs) during AF and AT procedures, AI-driven insights to assist electrophysiologists. |
| Target Medical Specialties | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and VX1+.